Rightscorp, Inc. (RIHT)

Longboard Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Revenue	0.83	0.78	0.83	0.93	0.32	0.1
Revenue Growth (YoY)	94.06%	-6.49%	-10.59%	187.25%	235.54%	1848.45%
Cost of Revenue	0.13	0.21	0.44	0.47	0.16	0.05
Gross Profit	0.7	0.56	0.39	0.47	0.16	0.05
Selling, General & Admin	1.92	2.11	3.78	3.34	1.94	1.1
Operating Expenses	1.99	2.2	3.89	3.4	1.97	1.12
Operating Income	-1.29	-1.63	-3.5	-2.93	-1.81	-1.08
Interest Expense	-0.02	-0.03	-0.01	-0.03	-0.3	-0.12
Other Non Operating Income (Expenses)	0.2	0.63	1.21	0.55	-	-
EBT Excluding Unusual Items	-1.1	-1.04	-2.3	-2.41	-2.11	-1.2
Legal Settlements	-0.32	-0.32	-1.14	-0.47	-	-
Other Unusual Items	-	-	-	0.02	0.07	-
Pretax Income	-1.42	-1.36	-3.43	-2.85	-2.04	-1.2
Net Income	-1.42	-1.36	-3.43	-2.85	-2.04	-1.2
Net Income to Common	-1.42	-1.36	-3.43	-2.85	-2.04	-1.2
Shares Outstanding (Basic)	137	120	94	73	38	10
Shares Outstanding (Diluted)	137	120	94	73	38	10
Shares Change (YoY)	19.18%	27.95%	29.06%	90.95%	299.57%	6.86%
EPS (Basic)	-0.01	-0.01	-0.04	-0.04	-0.05	-0.13
EPS (Diluted)	-0.01	-0.01	-0.04	-0.04	-0.05	-0.13
Free Cash Flow	-0.44	-0.81	-2.5	-2.94	-1.2	-0.66
Free Cash Flow Per Share	-0.00	-0.01	-0.03	-0.04	-0.03	-0.07
Gross Margin	84.17%	72.42%	47.16%	50.00%	50.04%	49.23%
Operating Margin	-154.75%	-209.72%	-420.28%	-315.19%	-558.87%	-1113.40%
Profit Margin	-170.86%	-174.21%	-412.70%	-306.50%	-630.46%	-1241.99%
Free Cash Flow Margin	-52.89%	-103.77%	-299.91%	-316.27%	-370.57%	-683.89%
EBITDA	-1.22	-1.54	-3.38	-2.87	-1.78	-1.05
EBITDA Margin	-146.13%	-198.36%	-	-	-	-
D&A For EBITDA	0.07	0.09	0.11	0.06	0.03	0.02
EBIT	-1.29	-1.63	-3.5	-2.93	-1.81	-1.08
EBIT Margin	-154.75%	-209.72%	-	-	-	-
Revenue as Reported	0.83	0.78	0.83	-	-	-
Advertising Expenses	-	-	-	-	0	0

Updated Nov 14, 2017. Source: S&P Global Market Intelligence. Standard template. Financial Sources.